Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer

MET inhibition is effective in some MET-amplified esophagogastric cancer (EGC) patients, but understanding acquired and de novo resistance mechanisms will be critical to improving therapy. We identified KRAS mutation as a novel cause of acquired resistance in a patient after a two-year response to M...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Discov
Κύριοι συγγραφείς: Kwak, Eunice L., Ahronian, Leanne G., Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T., Clark, Jeffrey W., Blaszkowsky, Lawrence S., Ryan, David P., Lennerz, Jochen K., Iafrate, A. John, Bardelli, Alberto, Hong, Theodore S., Corcoran, Ryan B.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2015
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670804/
https://ncbi.nlm.nih.gov/pubmed/26432108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0748
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια